

• Fosun News VOL.22 •



Henlius' first Domestically Developed Bio-similar Drug Hanlikang® was Launched



On April 27, 2019, Hanlikang®, the first domestically developed bio-similar drug by Fosun-owned Henlius Biotech was launched in Shanghai.

Hanlikang® is the first anti-tumor drug approved by the National Medical Products Administrations this year. It demonstrates high effectiveness and safety with high resemblance to the effects of the original rituximab during clinical testing. The successful launch of Hanlikang® will enhance the accessibility of bio-similar drug and provide new treatment options to the Chinese lymphoma patients, especially non-Hodgkin lymphoma patients.

Henlius Biotech attaches great importance to the product innovation and views it as the core value of the company. So far, over 20 monoclonal antibody drugs are in the process of research and development.



Yuyuan Signed an Investment Cooperation Agreement with IGI during The Second Belt and Road Forum



On April 25th, the Second Belt and Road Forum International Cooperation was officially held in Beijing. IGI Belgian International Gemological Institute, as one of the representatives of European companies, was invited to participate in this forum and signed an investment cooperation agreement with Yuyuan, Fosun's important flagship platform for happiness ecosystem.

As a world-famous jewelry appraisal laboratory, IGI has decades of experience and know-hows in the jewelry industry, with branches in Belgium, China, India, United Arab Emirates, Thailand and other countries.



Chinese Trailor for Ang Lee's New Film 'Gemini Killer' was Released



The action film "Gemini Killer", which is co-produced by Fosun Film, Paramount and Skydance, released its Chinese trailor. Directed by Ang Lee and starred by Will Smith, the movie will meet worldwide audience on October 11, 2019. The cast also includes Mary Elizabeth Winstead ('Blood Storm'), Cliff Owen, and Benedict King ('Doctor Strange') with Jerry Bruckheimer ('Pirates of the Caribbean', 'Pearl Harbor') as its producer.

End



复星国际00656.HK

投资者关系部

Issued by Investor

Relations Department

E-mail: ir@fosun.com



www.fosun.com

